Asieris Signs a Worldwide Development and Commercialization Agreement with Photocure for Cevira

Asieris Signs a Worldwide Development and Commercialization Agreement with Photocure for Cevira

Shots:

  • Photocure to receive $5M upfront within 6mos. after signing the agreement and $14M on the approval of the second indication in the US, China & EU with royalties on sales. Photocure will also receive $18M & $36M as a regulatory & clinical milestone in China & the US and EU respectively
  • The companies collaborated to develop & commercialize Cevira for the treatment of HPV induced cervical precancerous lesions. Asieris will be responsible for the manufacturing of the Cevira and Photocure will responsible for the manufacturing of API
  • Cevira is photo-dynamic drug-device combination therapy, being developed for non-surgical treatment of cervical dysplasia, placed on the cervix by the gynecologist with no disruption in normal activities

Click here to read full press release/ article | Ref: PRNewsWire | Image: Photocure